Accessibility Menu
Cochlear logo

Cochlear(OTC) CHEOF

Market Cap$6.21BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2003)+351%
5 Year-41%
1 Year-53%
1 Month+12%
$94.89
-1.96%
-1.90Today
Cochlear last closing stock price
MetricPriceDate
Last closeUSD 94.892026-08-31
Cochlear stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-1.92%USD 96.752026-08-24
1 month+12.04%USD 84.692026-07-31
3 month+33.46%USD 71.102026-06-02
Year to date-43.01%USD 166.502025-12-31
1 year-53.16%USD 202.572025-08-29
3 year-43.55%USD 168.092023-08-30
5 year-40.77%USD 160.212021-09-01
Since inception+351.02%USD 21.042003-06-30

Cochlear Financials at a Glance

Market Cap

$6.21BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

A$4.69B

Net Income (TTM)

A$536.16M

EPS (TTM)

$1.46

P/E Ratio

64.77

Dividend

$2.93

Beta (Volatility)

0.08 (Low)

Price

$94.89

Volume

357

Open

$94.89

Previous Close

$94.89

Daily Range

$94.89 - $94.89

52-Week Range

$64.39 - $207.71

Estimated Earnings Date

Feb 16, 2027

CHEOF News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Cochlear

Cochlear Limited is an Australian company founded in 1981, specializing in advanced implantable hearing technology. The company develops and distributes a range of auditory solutions for both pediatric and adult populations globally.

Products and Services
  • Cochlear implant devices for hearing restoration
  • Bone conduction systems for individuals with conductive hearing loss
  • Upgrades for sound processors and associated accessories
Growth Outlook
  • Projected revenue growth driven by increasing global demand for hearing solutions
  • Expansion into emerging markets to capture new customer segments
  • Investment in research and development to enhance product offerings
Financial Highlights
  • Recent quarterly revenue of AUD 1.18 billion, reflecting strong market performance
  • Net income of AUD 161 million, showcasing profitability
  • TTM dividend yield of 3.44%, indicating attractive returns for investors
Cochlear Limited stands out in the medical devices industry with its innovative products aimed at improving the quality of life for individuals with hearing impairments. The company's commitment to research and development positions it well for future growth, particularly as global awareness of hearing health increases. Recent financial performance highlights a robust revenue stream and profitability, making it an appealing option for potential investors interested in the healthcare sector. The company's strategic focus on expanding into emerging markets and enhancing its product lineup further supports its growth trajectory.
AI Generated • Aug 8, 2026

Industry

Healthcare Equipment and Supplies

Sector

Health Care

Employees

5,400

CEO

Diggory William Howitt, MBA

Website

www.cochlear.com

Headquarters

Sydney, NSW 2109, AU

CHEOF Financials

Key Financial Metrics (TTM)

Gross Margin

70.53%

Operating Margin

12.89%

Net Income Margin

6.31%

Return on Equity

8.01%

Return on Capital

15.41%

Return on Assets

5.66%

Earnings Yield

1.54%

Dividend Yield

3.09%

Payout Ratio

1.91%

Stock Overview

Market Cap

$6.21BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

65.40M

Volume

357

Avg. Volume

610.766

Financials (TTM)

Gross Profit

A$3.39B

Operating Income

A$826.60M

EBITDA

A$1.02B

Operating Cash Flow

A$605.22M

Capital Expenditure

-A$123.44M

Free Cash Flow

A$481.78M

Cash & ST Invst.

A$187.44M

Total Debt

A$212.40M

Cochlear Performance Analysis

Cochlear annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20232023-06-30AUD 1,315,608,22410.5%
20242024-06-30AUD 1,479,967,87812.5%
20252025-06-30AUD 1,525,689,0853.1%
20262026-06-30AUD 1,582,046,2783.7%
Cochlear sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22024-12-303.1%
Q42025-06-301.2%
Q22025-12-31-0.9%
Q42026-06-30-1.6%
Cochlear annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20232023-06-30AUD 3.07-3.7%
20242024-06-30AUD 3.5615.9%
20252025-06-30AUD 3.847.9%
20262026-06-30AUD 1.52-60.3%
Cochlear sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22024-12-3023.8%
Q42025-06-30-10.3%
Q22025-12-31-12.1%
Q42026-06-30-108.9%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2026YOY CHG

Revenue

A$1.16B

+1.8%

Gross Profit

A$788.79M

-8.4%

Gross Margin

68.17%

N/A

Market Cap

$6.21BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$1.15M

N/A

Employees

5,400

N/A

Net Income

-A$14.18M

-108.6%

EBITDA

A$134.41M

-46.7%

Quarterly Fundamentals

Name
Q4 2026YOY CHG

Total Cash

A$187.44M

-63.5%

Total Debt

A$212.40M

-12.8%

Accounts Receivable

A$558.42M

+13.8%

Inventory

A$490.61M

+25.3%

Long Term Debt

A$170.46M

-15.7%

Short Term Debt

A$41.94M

+0.8%

Return on Assets

5.66%

N/A

Return on Invested Capital

15.06%

N/A

Free Cash Flow

A$197.82M

+3.1%

Operating Cash Flow

A$230.88M

-0.4%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
ALBBYAlibaba Health Information Technology Limited
$7.87-1.69%
WILLFDemant A/S
$44.03+0.00%
WILYYDemant A/S
$22.70+0.00%
ERFSFEurofins Scientific SE
$86.96+1.41%

Trending Stocks

Symbol / CompanyPricePrice Chg
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$10.38+0.11%
NVDANvidia
$228.45+0.02%
SPCXSpace Exploration Technologies
$149.74+0.06%
BITOProShares Trust - ProShares Bitcoin ETF
$11.01+0.06%

Questions About CHEOF

What is the current price of Cochlear?

Cochlear is trading at $94.89 per share.

What is the 52-week range for Cochlear?

Over the past 52 weeks, Cochlear has traded between $64.39 and $207.71.

How much debt does Cochlear have?

As of the most recent reporting period, Cochlear reported total debt of A$147.36M.

How much cash does Cochlear have on hand?

Cochlear reported A$130.04M in cash and cash equivalents in its most recent financial results.

What is Cochlear’s dividend yield?

Cochlear currently has a dividend yield of 3.09%.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services